“Mustang balloon – they track very well through tight stenosis or through occlusions. They expand in a predictable way. You can use them easily. That’s not true of all the brands. its reliable and re-usable.
Coyote – it just traps very nicely through even long segment chronic occlusions it will track very well.
Nanocross – this a nice, tapered option because these vessels do get smaller as you go down towards the foot so there is less risk of causing injury to the more distal arteries. That is a nice feature of that balloon.”
– Interventional Radiologist, USA
Reimbursement of peripheral stenting and angioplasty does not have much difference; however, there is low uptake of carotid artery stenting due to stringent conditions for reimbursement.Physicians’ brand perception and their rank of medical device companies based on 15 KPIs such as technology, clinical evidence, patient outcome, etc. Moreover, diligent examination of physician’s brand usage and brand satisfaction levels, and the factors such as ease of use of the device, and cost-effectiveness among others effecting brand usage have been covered.
Future Trends for PAD treatment landscape show that Transcarotid Artery Revascularization TCAR has the potential to replace carotid endarterectomy. Development of early detection and optimal referral pathway are expected to increase procedure volumes for peripheral vascular interventions. The availability of new angioplasty techniques such as shockwave technology will have a positive impact on the procedure trends.
Competitor landscape covered in this report includes the recent approval of IN. PACT 018 a low-profile drug-coated balloon platform from Medtronic, the product is indicated for the treatment of peripheral arterial disease in superficial femoral and popliteal arteries; and the acquisition of Straub Medical AG, a developer of atherectomy and thrombectomy devices for PAD and venous diseases, by BD in 2020.
What’s in it for you?